Replies to post #199247 on Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

Posting history is a tell. OM is a unmet medical need. Brilacidin has the potential for standard of care use. Total 19 patients in interim report. Only 2 out of 9 patients in the Brilacidin (active arm) came down with severe OM Grade3 while 7 out of 10 in the placebo arm came down with severe OM.

Primary Efficacy Results Incidence of Severe OM (WHO Grade ≥ 3)

• Active Arm (Brilacidin): 2 of 9 patients (22.2 percent)
• Control Arm (Placebo): 7 of 10 patients (70 percent)